

Nectar Lifesciences Ltd.



Ref: NLL/CS/2014-567

Dated: 28.05.2014

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI - 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI - 400 001.

Ref. Minor Rectifications in the Annual results submitted.

Dear Sirs,

Please find attached herewith financial results with following minor corrections:

1. In column 3 of Part I, the figures for the quarter ended 31.03.2013 are Audited instead of Unaudited.
2. In column 7 of Part I, the point no. 15, the figures for the 'Reserve excluding the Revaluation Reserve' is Rs. 84517.96 instead of Rs. 76203.71.
3. In statement of Asset and Liabilities in column 4 of figures of 31.03.2013:
 - (a) the figure of point (ii) Reserves and Surplus under the head Shareholder's Fund is Rs. 84517.96 instead of Rs. 76203.71.
 - (b) the figure of point (ii) Other Current Liabilities under the head Current Liabilities is Rs. 13127.61 instead of Rs. 12986.90.
 - (c) the figure of total of Liabilities side is Rs. 227404.31 instead of Rs. 218949.35.
 - (d) the figure of point (iii) Long Term Loans & Advances under the Non Current Assets is Rs. 7048.61 instead of Rs. 6312.20.
 - (e) the figure of point (v) Short Term Loans & Advances under the Current Assets is Rs. 8684.33 instead of Rs. 10504.73.
 - (f) the figure of total of Assets side is Rs. 227404.31 instead of Rs. 228488.30.

Kindly take note of the above. Inconvenience caused due advertent mistake is deeply regretted.

Please acknowledge the receipt of the same.

Thanking you,

Yours faithfully,
For Nectar Lifesciences Limited


(Dinesh Dua)

Chief Executive Officer & Director



NECTAR LIFESCIENCES LIMITED

Corporate Identification Number (CIN): L24232PB1995PLC016664, Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab)

Part I - Financial Results for the Quarter and the year ended 31.03.2014

(Rs in Laacs)

S. No	PARTICULARS	Quarter ended 31-03-2014	Quarter ended 31-12-2013	Quarter ended 31-03-2013	Year ended 31-03-2014	Year ended 31-03-2013	Year ended 31-03-2014	Year ended 31-03-2013
		Audited (Stand-alone)	Unaudited (Stand-alone)	Audited (Stand-alone)	Audited (Stand-alone)	Audited (Stand-alone)	Audited (Consolidated)	Audited (Consolidated)
1.	Income from Operations							
	(a) Gross Sales	48218.07	40700.32	38233.34	170818.37	167324.71	170818.37	167324.71
	Less : Excise Duty	2177.98	1596.41	1469.48	7041.45	4843.28	7041.45	4843.28
	Net Sales	46040.09	39103.91	36763.86	163776.92	162481.43	163776.92	162481.43
	(b) Other Operating Income	34.07	6.80	10.20	54.29	143.67	54.29	143.67
	Total Income from Operations (net)	46074.16	39110.71	36774.06	163831.21	162625.10	163831.21	162625.10
2.	Expenses							
	(a) Cost of Materials consumed	36725.71	24867.91	23323.59	117267.14	114652.24	117267.14	114652.24
	(b) Purchase of Stock in Trade	147.16	577.99	663.98	3982.32	5999.80	3982.32	5999.80
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2590.51)	568.14	(1548.00)	(5781.06)	(6440.21)	(5781.06)	(6440.21)
	(d) Employee benefits expense	1173.69	1303.99	1498.92	5132.87	4861.11	5132.87	4861.11
	(e) Depreciation and amortisation expense	2076.06	2104.07	1961.03	8418.57	7595.61	8418.57	7595.61
	(f) Other expenses	3143.83	3841.16	4159.99	14353.11	14544.15	14353.11	14544.15
	Total Expenses	40675.94	33263.26	30059.51	143372.95	141212.70	143372.95	141212.70
3.	Profit from Operations before Other Income, finance costs and exceptional Items (1-2)	5398.22	5847.45	6714.55	20458.26	21412.40	20458.26	21412.40
4.	Other Income	90.45	244.40	366.61	1162.75	1604.03	1162.75	1604.03
5.	Profit before finance costs and exceptional Items (3+4)	5488.67	6091.85	7081.16	21621.01	23016.43	21621.01	23016.43
6.	Finance costs	3297.13	3983.04	3470.84	13798.74	11548.93	13798.74	11548.93
7.	Profit after finance costs but before exceptional Items (5-6)	2191.54	2108.81	3610.32	7822.27	11467.50	7822.27	11467.50
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	2191.54	2108.81	3610.32	7822.27	11467.50	7822.27	11467.50
10.	Tax Expense	321.88	395.75	1046.11	1614.28	2900.95	1614.28	2900.95
11.	Net Profit from ordinary activities after tax (9-10)	1869.66	1713.06	2564.21	6207.99	8566.55	6207.99	8566.55
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	1869.66	1713.06	2564.21	6207.99	8566.55	6207.99	8566.55
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2242.61	2242.61	2242.61	2242.61	2242.61	2242.61	2242.61
15.	Reserves excluding Revaluation Reserves				90,463.57	84,517.96	90,463.57	84,517.96
16.i	Earnings per Share (EPS) (before extraordinary items)							
	a) Basic	0.83	0.76	1.14	2.77	3.82	2.77	3.82
	b) Diluted	0.83	0.76	1.14	2.77	3.82	2.77	3.82
16.ii	Earnings per Share (EPS) (after extraordinary items)							
	a) Basic	0.83	0.76	1.14	2.77	3.82	2.77	3.82
	b) Diluted	0.83	0.76	1.14	2.77	3.82	2.77	3.82

Part II Select Information for the Quarter and Year Ended 31.03.2014

Particulars of shareholding								
1.	Public Shareholding							
	- Number of Shares	124792970	124792970	124792970	124792970	124792970	124792970	124792970
	- Percentage of Shareholding	55.65	55.65	55.65	55.65	55.65	55.65	55.65
2.	Promoters and Promoter Group Shareholding							
	a) Pledged/Encumbered							
	- Number of Shares	0	0	0	0	0	0	0
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	- Percentage of Shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	b) Non-encumbered							
	- Number of Shares	99468000	99468000	99468000	99468000	99468000	99468000	99468000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.35	44.35	44.35	44.35	44.35	44.35	44.35
3.	Investor Complaints	3 Months ended 31.03.2014						
	Pending at the beginning of Quarter	0						
	Received During the Quarter	17						
	Disposed Off During the Quarter	17						
	Pending at the end of Quarter	0						



Statement of Assets and Liabilities

PARTICULARS	(Rs in Lacs)			
	As at 31-03-2014	As at 31.03.2013	As at 31-03-2014	As at 31.03.2013
	Audited	Audited	Audited	Audited
	(Stand-alone)	(Stand-alone)	(Consolidated)	(Consolidated)
SHAREHOLDERS' FUND				
(i) Capital	2242.61	2242.61	2242.61	2242.61
(ii) Reserves and Surplus	90463.57	84517.96	90463.57	84517.96
NON CURRENT LIABILITIES				
(i) Long Term Liabilities	22333.80	26096.08	22333.80	26096.08
(ii) Deferred Tax Liability	11189.31	9575.63	11189.31	9575.63
(ii) Other Long Term Liabilities	80.75	102.99	80.75	102.99
(iii) Long Term Provisions	489.99	378.88	489.99	378.88
CURRENT LIABILITIES				
(i) Short Term Borrowings	57984.20	50911.14	57984.20	50911.14
(ii) Trade Payables	44006.09	38251.85	44006.09	38251.85
(iii) Other Current Liabilities	8671.49	13127.61	8671.49	13127.61
(iv) Short Term Provisions	1944.84	2199.56	1944.84	2199.56
Total	239,406.65	227,404.31	239,406.65	227,404.31
NON CURRENT ASSETS				
(i) Fixed Assets (Incl CWIP)	106980.66	105240.84	106980.66	105240.84
(ii) Non Current Investments	5.01	5.01	5.01	5.01
(iii) Long Term Loans & Advances	8686.72	7048.61	8686.72	7048.61
(iv) Other Non Current Assets	0.75	1.50	0.75	1.50
CURRENT ASSETS				
(i) Current Investments	31.36	31.92	31.36	31.92
(ii) Inventories	75842.67	67600.04	75842.67	67600.04
(iii) Trade Receivables	37664.86	34938.64	37664.86	34938.64
(iv) Cash & Bank Balances	997.77	624.04	997.77	624.04
(v) Short Term Loans & Advances	6582.90	8684.33	6582.90	8684.33
(vi) Other Current Assets	2613.96	3229.38	2613.96	3229.38
Total	239,406.65	227,404.31	239,406.65	227,404.31

Notes:

- The above financial results were reviewed by Audit Committee on 27.05.2014 and approved by the Board in its meeting held on 28.05.2014 and further Audited by the Statutory Auditors of the Company.
- The company is exclusively in the pharmaceutical business segment.
- The Board of Directors has recommended the Final Dividend of Re. 0.10/- per equity share (10% on the face value of Re. 1/- per equity share) for the financial year 2013-14, subject to the approval of Members at their Annual General Meeting.
- Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figure in respect of the full financial year ended 31st March and the unaudited published year to date figures upto the third quarter ended 31st December which was subject to limited review.

Dated: 28.05.2014
Place: Chandigarh

By Order of the Board of Directors
of Nectar Lifesciences Limited

(Dinesh Dua)
Chief Executive Officer & Director

